Clinical Trial

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-13.
Trial Details
NCT Number NCT05769660
Lead Sponsor BeyondBio Inc.
Conditions Glioblastoma Multiforme
Enrollment 12 participants
Start Date 2022-11-29
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-10